Anti-atherosclerotic activity of the calcium antagonist lacidipine in cholesterol-fed hamsters

Biomedicine and Pharmacotherapy

Volumn 54, Issue 2, 2000, Pages 93-99

  Cristofori, P ^a   Lanzoni, A ^a   Gaviraghi, G ^a   Turton, J ^b   Sbarbati, A ^c  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

Calcium antagonist; Hamster; Hypertension; Lacidipine; Ultrastructure

Indexed keywords

CALCIUM ANTAGONIST; LACIDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CELL ULTRASTRUCTURE; CHOLESTEROL DIET; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG EFFECT; HAMSTER; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TARGET CELL;

EID: 0034163867     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(00)88858-7     Document Type: Article

References (12)

1. Cristofori P, Terron A, Micheli D, Bertolini G, Gaviraghi G, Carpi C. Vascular protection of lacidipine in salt-loaded Dahl-s rats at nonsustained antihypertensive doses. J Cardiovasc Pharmacol 1991; 17 Suppl 14 : S75-S86.
2. Cristofori P, Sbarbati A, Accordini C, Terron A, Micheli D. Protective action of lacidipine in cardiac hypertrophy of the spontaneously hypertensive stroke-prone rat: An ultrastructural study. J Submicrose Cytol Pathol 1994; 26 : 331-40.
3. Gaviraghi G, Micheli M, Terron A, Cristofori P. Lacidipine: Prevention of vascular damage induced by hypertension. J Cardiovasc Pharmacol 1991; 118 Suppl 11 : S7-S12.
4. Ginsburg R, Davis K, Bristow MR, McKennett K, Kodsi SR, Billingham ME, et al. Calcium antagonists suppress atherogenesis in aorta but not in the intramural coronary arteries of cholesterol-fed rabbits. Lab Invest 1983; 49 : 154-58.
5. Hall ST, Harding SM, Evans GL, Pellegatti M, Rizzini P. Clinical pharmacology of lacidipine. J Cardiovasc Pharmacol 1991; 17 Suppl 4 : S9-S13.
6. Herbette C, Gaviraghi G, Tulenko T, Mason RP. Molecular interactions between lacidipine and biological membranes. J Hypertens 1993; 11 Suppl 1 : S13-S9.
7. Kowala MC, Nunnari JJ, Durham SK, Nicolasi RJ. Doxazosin and cholestyramine similarly decrease fatty streak formation in aortic arch of hyperlipidemic hamsters. Atherosclerosis 1991; 91 : 35-49.
8. Lichtor T, Davis HR, Vesselinovitch D, Wissler RW, Mullan S. Suppression of atherogenesis by nifedipine in the cholesterolfed rhesus monkey. Appl Pathol 1989; 7 : 8-18.
9. Micheli D, Ratti E, Toson G, Gaviraghi G. Pharmacology of lacidipine, a vascular-selective calcium antagonist. J Cardiovasc Pharmacol 1991; 17 Suppl 4 : SI-S8.
10. Nistor A, Bulla A, Filip DA, Radu A. The hyperlipidernic hamster as a model of experimental atherosclerosis. Atherosclerosis 1987; 68 : 159-73.
11. Skepper JN, Kappagoda CE. The effect of concurrent administration of isradipine on the development of fatty streaks in the cholesterol-fed rabbit: A morphometric study. Atherosclerosis 1992; 96 : 17-31.
12. Takasu N, Kurihara H, Uchida K. Early changes in fine structure of the aortic arch in hamsters fed a high cholesterol diet. Arch Histol Cytol 1990; 3 : 211-8.